Candesartan reduces cardiovascular events in patients on chronic haemodialysis

Nephrol Dial Transplant. 2007 Jan;22(1):281; author reply 281-2. doi: 10.1093/ndt/gfl646. Epub 2006 Nov 3.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Angiotensin II Type 1 Receptor Blockers / therapeutic use*
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use*
  • Biphenyl Compounds
  • Cardiovascular Diseases / drug therapy*
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / prevention & control*
  • Humans
  • Kidney Failure, Chronic / therapy*
  • Renal Dialysis / adverse effects*
  • Renal Dialysis / methods*
  • Renin-Angiotensin System
  • Tetrazoles / pharmacology
  • Tetrazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Benzimidazoles
  • Biphenyl Compounds
  • Tetrazoles
  • candesartan